Interpace OTC Stock Probability of Future OTC Stock Price Finishing Over 0.0

Interpace Biosciences' future price is the expected price of Interpace Biosciences instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Interpace Biosciences performance during a given time horizon utilizing its historical volatility. The current year Price to Sales Ratio is expected to grow to 0.77, whereas Price to Book Value is forecasted to decline to (0.76) .
  
Please see Interpace Biosciences Backtesting, Interpace Biosciences Valuation, Interpace Biosciences Correlation, Interpace Biosciences Hype Analysis, Interpace Biosciences Volatility, Interpace Biosciences History as well as Interpace Biosciences Performance. Please specify Interpace Biosciences time horizon, a valid symbol (red box) and a target price (blue box) you would like Interpace Biosciences odds to be computed.

Interpace Biosciences Target Price Odds to finish over 0.0

The tendency of Interpace OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.00 90 days 0.00 
close to 99
Based on a normal probability distribution, the odds of Interpace Biosciences to move above the current price in 90 days from now is close to 99 (This Interpace Biosciences probability density function shows the probability of Interpace OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Interpace Biosciences has a beta of 0.35. This usually indicates as returns on the market go up, Interpace Biosciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Interpace Biosciences will be expected to be much smaller as well. Additionally The company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Interpace Biosciences is significantly underperforming NYSE Composite.
   Interpace Biosciences Price Density   
       Price  

Predictive Modules for Interpace Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Interpace Biosciences. Regardless of method or technology, however, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Interpace Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Interpace Biosciences in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.000.0014.57
Details
Intrinsic
Valuation
LowReal ValueHigh
0.000.0014.57
Details
Earnings
Estimates (1)
LowProjected EPSHigh
-2.61-2.61-2.61
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Interpace Biosciences. Your research has to be compared to or analyzed against Interpace Biosciences' peers to derive any actionable benefits. When done correctly, Interpace Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Interpace Biosciences.

Interpace Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Interpace Biosciences is not an exception. The market had few large corrections towards the Interpace Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Interpace Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Interpace Biosciences within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.4
β
Beta against NYSE Composite0.35
σ
Overall volatility
0.28
Ir
Information ratio -0.06

Interpace Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Interpace Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Interpace Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Interpace Biosciences generated a negative expected return over the last 90 days
Interpace Biosciences has high historical volatility and very poor performance
Interpace Biosciences has some characteristics of a very speculative penny stock
The company currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M.
Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Interpace Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 28.0% of Interpace Biosciences shares are held by company insiders
Latest headline from news.google.com: Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern - Yahoo Finance

Interpace Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Interpace OTC Stock often depends not only on the future outlook of the current and potential Interpace Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Interpace Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding4195412.00

Interpace Biosciences Technical Analysis

Interpace Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Interpace OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Interpace Biosciences. In general, you should focus on analyzing Interpace OTC Stock price patterns and their correlations with different microeconomic environments and drivers.

Interpace Biosciences Predictive Forecast Models

Interpace Biosciences time-series forecasting models is one of many Interpace Biosciences' otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Interpace Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.

Things to note about Interpace Biosciences

Checking the ongoing alerts about Interpace Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Interpace Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Interpace Biosciences generated a negative expected return over the last 90 days
Interpace Biosciences has high historical volatility and very poor performance
Interpace Biosciences has some characteristics of a very speculative penny stock
The company currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M.
Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Interpace Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 28.0% of Interpace Biosciences shares are held by company insiders
Latest headline from news.google.com: Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern - Yahoo Finance

Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Please note, there is a significant difference between Interpace Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.